Dediabetes Logo
Evidence Hub
Learn what works
Latest Research
Newest studies
What Changed
Weekly intelligence
Settings
Login / Sign up

Cardiovascular Risk in Diabetes: Evidence and Outcomes

Evidence on improving cardiovascular risk

Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.

33
Studies
39
Evidence Pairs
Moderate Research
Evidence Base: 57/100

Evidence summary for AI and search

Among 33 indexed studies and 28 interventions, the strongest signals are summarized from deterministic graph patterns. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.

Dediabetes summarizes indexed research evidence for education and discovery. This content is not medical advice and should not replace guidance from a qualified clinician.

Supporting Studies

33

Research documents analyzed

Evidence Pairs

39

Intervention-outcome relationships

Latest Publication

Jun 2026
Powered by the Dediabetes Evidence Intelligence™ framework

Evidence Snapshot

Qualitative overview of the evidence landscape

Low Confidence

Based on 33 studies, emerging evidence suggests Semaglutide, Canagliflozin, Icosapent ethyl are the strongest-supported interventions for cardiovascular risk.

Evidence Intelligence™

Evidence Snapshot

A structured summary of where the evidence is strongest, mixed, or still emerging.

View all supporting studies

Evidence at a Glance

33
Studies
28
Interventions
7
Outcomes
0
Strong evidence signals
0
Mixed evidence areas
Evidence freshness
Jun 2026
Latest indexed
Evidence Story

Cardiovascular Risk evidence appears to center on Semaglutide.

Among 33 indexed studies and 28 interventions, the strongest signals are summarized from deterministic graph patterns. Semaglutide appears to be one of the clearer current evidence signals.

  • Evidence is consistently positive across multiple studies.
  • Some evidence is positive, but results are not consistent across all studies.
  • Early findings are encouraging, but stronger trials are needed.
Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Freshness

Latest indexed evidence: June 2026

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies
Evidence basis: 3 evidence pairs - 8 studies

Why this appears here

Moderate evidenceConsistent resultsPositive effect signalMultiple RCTs
Semaglutide
8 studies
EvidenceScore™
61/100
ConsensusScore™
63/100

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide
Empagliflozin
Semaglutide
8 studies
EvidenceScore™
61/100
ConsensusScore™
63/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results Present
Evidence basis: 10 evidence pairs - 14 studies
View supporting studies
Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Canagliflozin
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
3 studies
EvidenceScore™
59/100
ConsensusScore™
100/100

Why this appears here

Positive effect signalLimited study volumeEmerging Or Limited StrengthFew randomized trials
Evidence basis: 9 evidence pairs - 9 studies
View supporting studies

Practical Questions

Organized using the Dediabetes Evidence Intelligence™ framework.

What improves cardiovascular risk?

outcome achievement
Emerging Evidence

Semaglutide, Canagliflozin, and Icosapent ethyl are among the most studied approaches for Cardiovascular Risk.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 8 studies

  2. 2

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Emerging | EvidenceScore™ 58.8 | strong positive | ConsensusScore™ Unclear | 3 studies

  3. 3

    Canagliflozin

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 33 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.

Applicability

Population details were available for 1 of 33 supporting studies: Groups were well matched at baseline across demographic, glycemic, cardiovascular, surgical, and medication variables according to Tables 2 and 3.

33 supporting studies30 RCTs, 1 systematic reviewLatest publication: Jun 2026Updated: Jul 2026

Does Semaglutide improve cardiovascular risk?

intervention effectiveness
Emerging Evidence

Semaglutide appears to improve Cardiovascular events.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 8 studies

Why this answer: This answer is based on 8 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
8 supporting studies8 RCTsUpdated: Jul 2026

Does Canagliflozin improve cardiovascular risk?

intervention effectiveness
Emerging Evidence

Canagliflozin appears to improve Cardiovascular events.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Canagliflozin

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Does Icosapent ethyl improve cardiovascular risk?

intervention effectiveness
Emerging Evidence

Icosapent ethyl appears to improve Cardiovascular events.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Icosapent ethyl

    EvidenceScore™ Emerging | EvidenceScore™ 55.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
  • Consistency cannot yet be determined.
  • Population details are unavailable.
1 supporting study1 RCTUpdated: Jul 2026

Semaglutide vs Canagliflozin for cardiovascular risk?

compare
Emerging Evidence

Semaglutide and Canagliflozin have available evidence for Cardiovascular Risk, but the comparison requires review of the underlying studies.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 8 studies

  2. 2

    Canagliflozin

    EvidenceScore™ Emerging | EvidenceScore™ 56.7 | strong positive | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 9 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.
  • Population details are unavailable.
9 supporting studies9 RCTsUpdated: Jul 2026

How can I lower cardiovascular events?

sub outcome
Limited Evidence

Semaglutide, Canagliflozin, and Icosapent ethyl are among the most studied approaches for Cardiovascular events.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 3 studies

  2. 2

    Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

    EvidenceScore™ Emerging | EvidenceScore™ 58.8 | strong positive | ConsensusScore™ Unclear | 1 study

  3. 3

    SMS text messaging behavioral intervention for health promotion

    EvidenceScore™ Limited | EvidenceScore™ 37.0 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.
  • Population details are unavailable.
6 supporting studies5 RCTs, 1 systematic reviewLatest publication: May 2026Updated: Jul 2026

What has the strongest evidence for cardiovascular risk?

evidence strength
Moderate Evidence

Semaglutide have the strongest available evidence signals in this evidence set.

ConsensusScore™: Results are consistent across studies.

Ranked evidence signals

  1. 1

    Semaglutide

    EvidenceScore™ Moderate | EvidenceScore™ 60.6 | strong positive | ConsensusScore™ Consistent | 3 studies

Why this answer: This answer is based on 3 supporting studies with consistent results and a positive effect signal.

Limitations

  • Population details are unavailable.
3 supporting studies3 RCTsUpdated: Jul 2026

Which interventions need more research for cardiovascular risk?

research gaps
Limited Evidence

More research is needed before firm conclusions can be drawn.

ConsensusScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Oral multivitamins and multiminerals (OMVM)

    EvidenceScore™ Limited | EvidenceScore™ 38.1 | neutral | ConsensusScore™ Consistent | 1 study

  2. 2

    SMS text messaging behavioral intervention for health promotion

    EvidenceScore™ Limited | EvidenceScore™ 37.0 | neutral | ConsensusScore™ Unclear | 1 study

  3. 3

    Vitamin D supplementation

    EvidenceScore™ Limited | EvidenceScore™ 37.0 | neutral | ConsensusScore™ Unclear | 1 study

Why this answer: This answer is based on 4 supporting studies and existing graph evidence signals.

Limitations

  • Consistency cannot yet be determined.
  • Population details are unavailable.
4 supporting studies4 RCTsUpdated: Jul 2026

Top evidence-backed options for this outcome

Interventions with the strongest supporting evidence in our database

Semaglutide

6 studies
View evidence

Canagliflozin

1 study
View evidence

Icosapent ethyl

1 study
View evidence

Canagliflozin combined with Metformin

1 study
View evidence

SGLT2 inhibitors

2 studies
View evidence

Structured multidisciplinary case management

1 study
View evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

2 studies
View evidence

Exercise therapy

1 study
View evidence

Less tight glycemic control

1 study
View evidence

Tighter glycemic control

1 study
View evidence

Note: EvidenceScore™ and ConsensusScore™ values are provided by the Evidence Intelligence™ read model when available. Click any option to explore the supporting research in our archive.

Strongest evidence signals

Key patterns and insights identified across the research landscape

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Strong positive signal

Semaglutide shows strong evidence for improving Cardiovascular events

Semaglutide → Cardiovascular events

Across 3 studies, Semaglutide shows a consistent strong positive signal for Cardiovascular events.

3 studies
EvidenceScore™: 60.550000000000004/100
View supporting studies
Strong positive signal

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows strong evidence for improving Cardiovascular events

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular events

Across 1 study, Finerenone (nonsteroidal mineralocorticoid receptor antagonist) shows a strong positive signal for Cardiovascular events.

1 studies
EvidenceScore™: 58.75/100
View supporting studies
Moderate positive signal

Semaglutide may improve Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 5 studies, Semaglutide shows a moderate positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

5 studies
EvidenceScore™: 57.69/100
View supporting studies
Strong positive signal

Canagliflozin shows strong evidence for improving All-cause mortality

Canagliflozin → All-cause mortality

Across 1 study, Canagliflozin shows a strong positive signal for All-cause mortality.

1 studies
EvidenceScore™: 56.650000000000006/100
View supporting studies
Strong positive signal

Canagliflozin shows strong evidence for improving Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Canagliflozin → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 1 study, Canagliflozin shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

1 studies
EvidenceScore™: 56.650000000000006/100
View supporting studies

Supporting Research

Selected studies that best represent the evidence behind this topic.

Click any study to view the full research summary, or click interventions and outcomes to filter the archive.

Explore all supporting studies

Browse the complete evidence archive for this topic, including interventions, outcomes, and related research.

View All Supporting Studies

Filter by study type, publication date, effect size, and more to refine your research